RESUMO
PURPOSE OF REVIEW: This review will address recent developments in the transfusion management of massively transfused trauma patients, focusing on the use of fixed blood component ratios in massive transfusion protocols. RECENT FINDINGS: The majority of trauma centers have migrated from laboratory-based transfusion protocols to massive transfusion protocols with fixed blood component ratios. These protocols with red blood cellâ: plasmaâ: platelet ratio of 1â:â1â:â1 are associated with improved survival in severely injured patients. However, alternate ratios have also demonstrated improved survival. Thus, the optimal ratio has not been determined. In addition, the use of medications, such as antifibrinolytics, and point of care testing, such as thromboelastography, are increasingly being used as part of massive transfusion protocols to adjust transfusion therapy and decrease bleeding. However, their optimal integration has yet to be determined. SUMMARY: Massive transfusion protocols with fixed ratios of red blood cells to plasma and platelets have improved survival in both civilian and military trauma patients. Continued studies of ratios as well as integration of other therapies and testing are ongoing in order to continue to improve patient outcome.
Assuntos
Transfusão de Componentes Sanguíneos/métodos , Transtornos Hemorrágicos/terapia , Ferimentos e Lesões/terapia , Protocolos Clínicos , HumanosRESUMO
BACKGROUND: The utility of convalescent coronavirus disease 2019 (COVID-19) plasma (CCP) in the current pandemic is not well defined. We sought to evaluate the safety and efficacy of CCP in severely or life threateningly ill COVID-19 patients when matched with a contemporaneous cohort. METHODS: Patients with severe or life-threatening COVID-19 were treated with CCP according to Food and Drug Administration criteria, prioritization by an interdisciplinary team, and based on CCP availability. Individual-level matched controls (1:1) were identified from patients admitted during the prior month when no CCP was available. The safety outcome was freedom from adverse transfusion reaction, and the efficacy outcome was a composite of death or worsening O2 support. Demographic, clinical, and laboratory data were analyzed by univariate and multivariable regression analyses accounting for matched design. RESULTS: Study patients (n = 94, 47 matched pairs) were 62% male with a mean age of 58, and 98% (90/94) were minorities (53% Hispanic, 45% Black, non-Hispanic) in our inner-city population. Seven-day composite and mortality outcomes suggested a nonsignificant benefit in CCP-treated patients (adjusted hazard ratio [aHR], 0.70; 95% CI, 0.23-2.12; P = .52; aHR, 0.23; 95% CI, 0.04-1.51; P = .13, respectively). Stratification by pretransfusion mechanical ventilation status showed no differences between groups. No serious transfusion reactions occurred. CONCLUSIONS: In this short-term matched cohort study, transfusion with CCP was safe and showed a nonsignificant association with study outcomes. Randomized and larger trials to identify appropriate timing and dosing of CCP in COVID-19 are warranted. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04420988.